Medicxi will use the €500m kitty to continue supporting drug hunters and entrepreneurs in creating asset-focused ...

Sarepta has received US FDA approval for updated prescribing information for Elevidys, an AAV-based gene transfer therapy.

MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

The US Food and Drug Administration (FDA) has a new chief drug regulator, with industry veteran Dr Richard Pazdur taking the ...

The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...

One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war to acquire ...

If successful in the Phase III trial, VK2735 would enter direct competition with established dual agonists such as Eli ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

Eisai and Biogen have announced UK MHRA approval for Leqembi for intravenous (IV) maintenance dosing to treat early Alzheimer ...

Investments will bolster clinical and commercial capacity in US and Europe facilities for injectable and oral solid dose ...